ERBB2 and cancer: Thus, our tests with the expression of the X-chromosome genes in male and female cancer patients, and with marker genes for the hormone-dependent vs. HER2-positive vs. triple-negative breast cancers confirmed the best performance of the Sh1 and Sh2PBR modes over other methods tested.